"We are a multi-provider allergy and asthma practice dedicated to helping the people of South Georgia."

During the past decade, Georgia Pollens Clinical Research Centers, Inc. conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 6 clinical trials were completed, i.e. on average, 54.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Georgia Pollens Clinical Research Centers, Inc." #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Baxalta now part of Shire" with 2 trials sponsored, "LEO Pharma" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Georgia Pollens Clinical Research Centers, Inc." #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Georgia Pollens Clinical Research Centers, Inc." are "Asthma" (7 trials), "Atopic Dermatitis" (6 trials), "Primary Immunodeficiency Diseases (PID)" (2 trials), "Food Hypersensitivity" (1 trials) and "Perennial Allergic Rhinitis" (1 trials). Many other conditions were trialed in "Georgia Pollens Clinical Research Centers, Inc." in a lesser frequency.

Most popular intervention types in "Georgia Pollens Clinical Research Centers, Inc." are "Drug" (12 trials), "Biological" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Lebrikizumab" (5 trials), "Omalizumab" (3 trials), "HYQVIA" (2 trials) and "0.15% azelastine hydrochloride" (1 trials). Other intervention names were less common.

The vast majority of trials in "Georgia Pollens Clinical Research Centers, Inc." are 19 trials for "All" genders.

Currently, there are NaN active trials in "Georgia Pollens Clinical Research Centers, Inc.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Georgia Pollens Clinical Research Centers, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Georgia Pollens Clinical Research Centers, Inc., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".